Latest News - Pfizer
Top Corporates Hub
Pfizer
Wellcome Leap Appoints John Young and Thomas Glanzmann to Board of Directors
09.09.2026 15:00
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Wellcome Leap (Leap), a U.S. nonprofit founded by the Wellcome Trust to accelerate breakthroughs in human health, today announced that John Young and Thomas Glanzmann have joined its Board of Directors. “Throughout my career, I have seen what becomes possible when exceptional science is matched with urgency, clear goals, and the ability to operate at scale,” said John Young. “Wellcome Leap brings those elements together in a unique way – assembling m
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
04.09.2026 14:42
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
04.09.2026 09:00
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
04.09.2026 01:07
Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...
Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check
04.09.2026 00:22
Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...
Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today?
03.09.2026 04:51
Pfizer, GitLab, and Conoco Phillips shares surged to 52-week highs on Wednesday amid a series of positive company catalysts and optimistic Wall Street coverage.
ExchangeRight Fully Subscribes $63.34 Million Net-Leased Portfolio 74 DST
02.09.2026 15:02
PASADENA, Calif., September 02, 2026--ExchangeRight has announced the full subscription of Net-Leased Portfolio 74 DST.
PACS Group Shares Rise 3.3% as Company Plans Florida Expansion and Completes More Eduro Acquisitions
02.09.2026 14:58
PACS Group, Inc. (NYSE:PACS) shares rose 3.
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway
02.09.2026 14:56
Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.
Definitive Healthcare Shares Rise 13% After Advent International Submits $1.02-Per-Share Proposal
02.09.2026 14:55
Definitive Healthcare Corp. (NASDAQ:DH) shares rose 13% on Wednesday after Advent International submitted a non-binding proposal to acquire shares and units it does not already own for $1.
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
02.09.2026 14:54
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
Centene Stock Roars Back 117% in a Year: Is CNC Still a Buy?
02.09.2026 14:46
CNC's 117% rally now has support from improving margins, firmer pricing and higher earnings expectations, while valuation remains below key peers.
Is Henry Schein (HSIC) Stock Undervalued Right Now?
02.09.2026 14:40
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
02.09.2026 14:40
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Centene (CNC) a Great Value Stock Right Now?
02.09.2026 14:40
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
02.09.2026 14:40
Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
02.09.2026 14:40
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Brokers Suggest Investing in UnitedHealth (UNH): Read This Before Placing a Bet
02.09.2026 14:30
The average brokerage recommendation (ABR) for UnitedHealth (UNH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Can Ensign Group's Operating Model Drive Growth Beyond Acquisitions?
02.09.2026 14:25
ENSG's decentralized model is driving organic growth through higher occupancy, stronger clinical results and improved productivity across its facilities.
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
02.09.2026 14:20
AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.